Cannabis Law Report

AUGUST 27, 2021

The Rules will be effective until at least August 19, 2022. The Rules aim to promote social equity, safety and easy access to the cannabis marketplace while keeping local municipalities in control of how they want cannabis businesses to operate in their jurisdiction. There are two types of fees: application fees and license fees.

Cultivation 105

Cultivation Conditions Business Cannabis 105

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

AUGUST 23, 2021

Analysts predict that pet-and-animal product sales are among the fastest-growing sectors in the CBD market with estimated sales reaching $125 million by 2022. He added that significant data is still needed to inform policy regarding use of consumer cannabis products. WRITTEN BY: Womble Bond Dickinson. Heather Hatcher, Ph.D.

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

JUNE 19, 2022

June 14, 2022 02:00 AM Eastern Daylight Time. Beckley Psytech will use Ksana Health’s Effortless Assessment Research System (EARS), an end-to-end solution for mobile sensing, to collect passive mobile device meta data from clinical trial participant’s smartphones, in order to identify individual signals of potential response and relapse.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

MAY 19, 2022

FDA states it has serious safety concerns with delta-8 THC. FDA states it has received 104 reports of adverse events in patients who consumed delta-8 THC products between December 1, 2020 and February 28, 2022. FDA considers delta-8 THC to pose serious health and safety risks. FDA Warning Letters. meat, milk, and eggs).

THC 52

THC CBD Food Pets 52

Cannabis Law Report

MAY 6, 2022

May 6, 2022. The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Michelle R.E.

THC 52

THC CBD Media Food 52

Cannabis Law Report

JUNE 1, 2021

Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022. opportunities in Fiscal 2022.” In Q1 2022, Canopy has expanded its portfolio of THC beverages with Tweed Iced Tea beverages (available in lemon and raspberry flavors, both with 5 mg THC) now shipping. Net revenue. Adjusted EBITDA 3.

Data 95

Data Vaping Supply Chain Business 95

Freedom Leaf

OCTOBER 15, 2018

Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. On July 23, the World Health Organization’s Expert Committee on Drug Dependence stated that “no public health problems have been associated with CBD use” and that “CBD has been found to be generally well tolerated with a good safety profile.”

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Fast Track review is for drugs that treat serious conditions and fill an unmet medical need.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

JANUARY 5, 2022

Despite the restrictions on research as a result of the Schedule I classification of cannabis, researchers have made many remarkable strides in proving the efficacy and safety of cannabis on the aforementioned conditions. . While Biden is receiving a lot of heat as a result of his inaction, many feel it is deserved.

Legislation 52

Legislation Cannabis Therapy Access 52

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

AUGUST 6, 2021

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).

Vaping 105

Vaping Research and Development Data Business 105

Cannabis Law Report

DECEMBER 16, 2021

Because recreational use of marijuana is increasing, especially as more states legalize it, the CDC believes it’s important for all workplaces to implement and address marijuana policies in their motor vehicle safety programs. Uber Canada Announces Partnership With Tokyo Smoke for Cannabis Ordering in Ontario.

Cannabinoids 52

Cannabinoids Retail Policy Cultivation 52

Cannabis Law Report

OCTOBER 29, 2021

NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. The primary endpoint of this Phase 1 trial was safety and tolerability. We expect to report this data as it becomes available and after submission to the FDA.

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: [link] Accessed October 17, 2022. February 2, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

MAY 6, 2022

On May 4, 2022, the FDA issued five warning letters to companies for selling products containing hemp-derived Delta-8 THC. Previously, the agency issued and updated a consumer advisory outlining consumer safety concerns relating to Delta-8 products. FDA Notes Additional Safety Concerns.

Hemp 52

Hemp Food Safety THC 52

Cannabis Law Report

MAY 26, 2022

was published in the Journal of Safety Research and made available online on May 18. Journal of Safety Research. Available online 18 May 2022. In Europe, however, researchers measured driving performance in normal traffic under THC alone, THC combined with alcohol, and placebo conditions. An additional. Funding support.

Dispensary 52

Dispensary Research and Development Safety Recreational 52

The Cannigma

JANUARY 13, 2023

Migraines are a peculiarly painful condition. Scientists still don’t understand exactly why migraines happen, nor how to cure the condition – but perhaps cannabis can help. A primary headache, such as a migraine, is its own condition, and not caused by a separate condition.

Terpenes 132

Terpenes Strains THC Treatment 132

Veriheal

MAY 17, 2022

The danger of exposure to fine particulate matter lies in the fact that these particles are able to “travel deeply into the respiratory tract, reaching the lungs,” which can then cause lung irritation, coughing, sneezing, shortness of breath, worsening lung function, and even worsening conditions such as asthma and heart disease.

Concentrates 98

Concentrates Data Conditions Cannabis 98

Cannabis Law Report

FEBRUARY 2, 2022

As federal legalization edges closer to reality, we believe the United States government will likely increase its role in setting the quality, consistency, and safety standards for medical and recreational cannabis products. million if the revenue generated from Lab Society’s products reaches certain milestones in 2022 and 2023.

Extraction 52

Extraction Pharmaceutical Hemp Cultivation 52

Cannabis Law Report

AUGUST 23, 2022

– August 23, 2022) – Silo Wellness Inc. One of Silo Wellness’s most valuable assets is its data. “We can significantly lower the cost by making air conditioning optional, for example, or provide a dorm room with bunk beds right alongside a luxury villa on the same site. Here’s the press release.

Microdosing 52

Microdosing Therapy Media Conditions 52

Cannabis Law Report

JUNE 25, 2021

According to the federal government, the Cannabis Act’s three stated objectives are to (i) keep cannabis out of the hands of young people, (ii) keep profits out of the pockets of criminals, and (iii) protect public health and safety by allowing adults to access legal cannabis. Level of Regulation.

Cannabinoids 91

Cannabinoids Edibles Retail Cannabis 91

The Cannigma

JULY 9, 2023

The fact that THC binds with important cannabinoid receptors in the brain, and the fact that THC can pass from the mother through the placenta to the developing fetus indeed raises questions about the safety of exposing an unborn baby to THC. A 2022 systematic review and meta-analysis that reviewed data from approximately 5.5

Research and Development 68

Research and Development THC Cannabinoids Topical 68

Cannabis Law Report

NOVEMBER 26, 2021

Topline results are expected in Q1 2022. We expect to commence enrollment in our pivotal Phase III liver cancer and Phase IIb NASH studies, as we look forward to topline results from our Phase III in psoriasis in the first quarter of 2022. dollars in thousands (except for share and per share data). . . Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

The Cannigma

FEBRUARY 1, 2023

Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. Work together to weigh the potential benefits and risks specific to your medical condition, and track the progress of your cancer along with your cannabis regimen. 1 So can cannabis cure cancer?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

DECEMBER 7, 2021

A full report of the anonymized, aggregate findings will be released in early 2022. The Radicle approach eliminates all physical infrastructure and instead collects data directly from participants as they go about their day-to-day life, in their real world environment. This open label RCT examined 13 U.S. in less than four days.

Clinical Trials 52

Clinical Trials CBD Data Sleep 52

Cannabis Law Report

NOVEMBER 29, 2021

As we approach the 2022 legislative session and the elections next November, it is important for lawmakers of all political persuasions to recognize that advocating for marijuana policy reforms is a political opportunity, not a political liability,” NORML’s Paul Armentano said. The law will take effect in January 2022. California.

Legislation 98

Legislation Patients Retail Access 98

Cannabis Law Report

MAY 14, 2022

Based upon the significant public concern for safety and lack of scientific and public health data related to the conversion process, the state’s Cannabis Regulatory Agency withdrew the proposed rulemaking. The program was officially adopted during the 2022 legislative session.

Banking 52

Banking Recreational Research and Development Cannabis 52

Cannabis Law Report

NOVEMBER 15, 2021

These platforms are currently monitored by state regulators and allow them to run forensic data analytic programs to inspect for deviations in declared yields or conversions such that regulators can spot potentially illegal diversions of regulated inventory by any licensee.

Programs 98

Programs Food Business Seed-To-Sale 98